NR546 Final Psychopharmacology Exam
Question and Answer | Grade A+ | Complete
Verified Guide
• Bipolar disorder treatment -✓✓Combine antidepressants with mood stabilizers.
• SNRI breastfeeding caution -✓✓Monitor infant irritability when prescribing
SNRIs.
• Antidepressant prescribing factors -✓✓Consider client preference, comorbidities,
and interactions.
• Initial antidepressant dosing -✓✓Start at lowest dose for 4-8 weeks.
• Citalopram dosage for elderly -✓✓Reduce dose to half for older patients.
• Paroxetine contraindication -✓✓Avoid in patients with history of falls.
• SSRI screening requirements -✓✓Check blood pressure before and during SNRI
treatment.
• SSRI suicide risk age group -✓✓Kids and adults under 25 are at higher risk.
• Escitalopram interactions -✓✓Has the least CYP interactions among SSRIs.
• Fluoxetine half-life -✓✓Longest acting with a half-life of 1-2 weeks.
• Discontinuation syndrome -✓✓More likely with paroxetine after stopping.
• Sertraline safety -✓✓Safe for use in nursing and pregnancy.
• Paroxetine pregnancy risk -✓✓Contraindicated due to atrial septal defect risk.
• Adjunct medications -✓✓Bupropion and mirtazapine have lowest sexual side
effects.
, • Serotonin syndrome -✓✓Occurs with two serotonergic drugs; causes agitation.
• Serotonin syndrome symptoms -✓✓Includes mental status changes and
autonomic instability.
• MAOIs black box warning -✓✓Suicidal ideation risk in youth.
• MAOI half-life -✓✓Typically ranges from 2-4 hours.
• SSRIs black box warning -✓✓Indicates risk of suicidal tendencies.
• MAOIs function -✓✓Inhibit enzyme that deactivates neurotransmitters.
• MAOI side effects -✓✓Include anticholinergic effects and weight gain.
• Hypertensive crisis risk -✓✓Occurs with tyramine-containing foods and MAOIs.
• Lithium -✓✓Mood stabilizer affected by NSAIDs and ACE inhibitors.
• NSAIDs -✓✓Nonsteroidal anti-inflammatory drugs that increase lithium levels.
• ACE Inhibitors -✓✓Medications that can elevate lithium levels.
• Caffeine -✓✓Substance that decreases lithium levels.
• Mania -✓✓Condition that reduces lithium levels in the body.
• L-Methylfolate -✓✓Bioavailable folate form aiding monoamine synthesis.
• Folic Acid -✓✓Dietary source of l-methylfolate, often deficient.
• Adjunctive Treatment -✓✓Supplemental therapy alongside primary depression
treatment.
• 6-(S)-5-methyl-tetrahydrofolate -✓✓Active form of l-methylfolate in the brain.
• Congenital Defects -✓✓Birth anomalies linked to paroxetine use in pregnancy.
Question and Answer | Grade A+ | Complete
Verified Guide
• Bipolar disorder treatment -✓✓Combine antidepressants with mood stabilizers.
• SNRI breastfeeding caution -✓✓Monitor infant irritability when prescribing
SNRIs.
• Antidepressant prescribing factors -✓✓Consider client preference, comorbidities,
and interactions.
• Initial antidepressant dosing -✓✓Start at lowest dose for 4-8 weeks.
• Citalopram dosage for elderly -✓✓Reduce dose to half for older patients.
• Paroxetine contraindication -✓✓Avoid in patients with history of falls.
• SSRI screening requirements -✓✓Check blood pressure before and during SNRI
treatment.
• SSRI suicide risk age group -✓✓Kids and adults under 25 are at higher risk.
• Escitalopram interactions -✓✓Has the least CYP interactions among SSRIs.
• Fluoxetine half-life -✓✓Longest acting with a half-life of 1-2 weeks.
• Discontinuation syndrome -✓✓More likely with paroxetine after stopping.
• Sertraline safety -✓✓Safe for use in nursing and pregnancy.
• Paroxetine pregnancy risk -✓✓Contraindicated due to atrial septal defect risk.
• Adjunct medications -✓✓Bupropion and mirtazapine have lowest sexual side
effects.
, • Serotonin syndrome -✓✓Occurs with two serotonergic drugs; causes agitation.
• Serotonin syndrome symptoms -✓✓Includes mental status changes and
autonomic instability.
• MAOIs black box warning -✓✓Suicidal ideation risk in youth.
• MAOI half-life -✓✓Typically ranges from 2-4 hours.
• SSRIs black box warning -✓✓Indicates risk of suicidal tendencies.
• MAOIs function -✓✓Inhibit enzyme that deactivates neurotransmitters.
• MAOI side effects -✓✓Include anticholinergic effects and weight gain.
• Hypertensive crisis risk -✓✓Occurs with tyramine-containing foods and MAOIs.
• Lithium -✓✓Mood stabilizer affected by NSAIDs and ACE inhibitors.
• NSAIDs -✓✓Nonsteroidal anti-inflammatory drugs that increase lithium levels.
• ACE Inhibitors -✓✓Medications that can elevate lithium levels.
• Caffeine -✓✓Substance that decreases lithium levels.
• Mania -✓✓Condition that reduces lithium levels in the body.
• L-Methylfolate -✓✓Bioavailable folate form aiding monoamine synthesis.
• Folic Acid -✓✓Dietary source of l-methylfolate, often deficient.
• Adjunctive Treatment -✓✓Supplemental therapy alongside primary depression
treatment.
• 6-(S)-5-methyl-tetrahydrofolate -✓✓Active form of l-methylfolate in the brain.
• Congenital Defects -✓✓Birth anomalies linked to paroxetine use in pregnancy.
